奈瑞肽在急性缺血性卒中早期时间窗入组患者中的安全性和有效性:三项随机试验个体患者数据的事后荟萃分析
本事后个体患者数据荟萃分析纳入ESCAPE-NA1、ESCAPE-NEXT和FRONTIER三项试验中卒中发作3小时内入组、接受奈瑞肽或安慰剂并选择再灌注治疗的患者,共690例。奈瑞肽组第90天应答者比例高于安慰剂组(56% vs 48%,aOR 1.48,95%CI 1.07-2.06,p=0.017),两组死亡率无显著差异,未发现安全性问题。作者认为奈瑞肽可能对3小时内选择再灌注的患者有神经保护作用,该入选标准需在未来试验中验证。
要点
- 卒中发作3小时内入组并选择再灌注的患者中,奈瑞肽组第90天应答者占56%,安慰剂组占48%,aOR 1.48(95%CI 1.07-2.06,p=0.017)。
- 奈瑞肽组死亡16%(62/389),安慰剂组死亡18%(55/301),aOR 0.81(95%CI 0.53-1.24,p=0.34),两组无显著差异。
- 两组均未发现安全性问题;作者认为奈瑞肽可能对3小时内选择再灌注的患者有神经保护作用,该入选标准需在未来试验中验证。
核心结论
- 奈瑞肽在包括改良Rankin量表评分、卒中恶化发生率和梗死体积在内的多项结局指标上显示出临床显著获益。
- 因此,奈瑞肽神经保护可能适用于卒中发作3小时内且选择再灌注的患者。
- 这些入选标准应在未来试验中验证。
研究设计与样本
- 本分析为事后个体患者数据荟萃分析,汇总ESCAPE-NA1、ESCAPE-NEXT和FRONTIER三项试验的数据。
- 三项试验在13个国家(加拿大、澳大利亚、德国、爱尔兰、意大利、荷兰、挪威、新加坡、韩国、瑞典、瑞士、英国和美国)的135个卒中中心进行。
- 纳入所有卒中发作3小时内入组、接受研究药物(奈瑞肽或安慰剂,1:1随机)并选择溶栓、血管内取栓或两者兼有的再灌注治疗的患者。
- 2015年3月26日至2023年1月31日期间,三项试验共入组2487例参与者,其中690例符合本汇总分析标准(奈瑞肽组389例,安慰剂组301例)。
- 690例参与者中男性364例(53%),女性326例(47%);中位年龄76岁(IQR 66-83),中位基线美国国立卫生研究院卒中量表评分为17(11-21)。
主要发现
- 奈瑞肽组第90天应答者为216/389(56%),安慰剂组为144/301(48%),aOR 1.48(95%CI 1.07-2.06;p=0.017)。
- 奈瑞肽组死亡62/389(16%),安慰剂组死亡55/301(18%),aOR 0.81(95%CI 0.53-1.24;p=0.34)。
- 两组均未发现安全性问题。
关键数值与推荐
- 主要终点为第90天应答者数量,定义为按照各自试验预设主要终点判定为结局良好的患者。
- 主要终点采用逻辑回归分析,校正年龄、卒中严重程度和试验。
临床怎么用
- 作者认为,奈瑞肽神经保护可能适用于卒中发作3小时内且选择再灌注的患者,这些入选标准应在未来试验中验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In three neuroprotection trials of nerinetide for acute ischaemic stroke, inconclusive results have been reported with respect to the prespecified primary outcome. However, none of the trials faithfully replicated the inclusion criteria of the animal studies that provided the rationale for the clinical trials-ie, treatment within 3 h of stroke onset and selected for reperfusion without previous thrombolysis. We aimed to investigate whether a clinical benefit of nerinetide might be seen in the subgroup of patients enrolled in these three clinical trials who met the criteria used in the animal studies. METHODS: In this post-hoc individual patient data meta-analysis, we pooled data from the ESCAPE-NA1, ESCAPE-NEXT, and FRONTIER trials, which were done at 135 stroke centres in 13 countries (Canada, Australia, Germany, Ireland, Italy, the Netherlands, Norway, Singapore, South Korea, Sweden, Switzerland, the UK, and the USA). We included all participants who were enrolled within 3 h of acute ischaemic stroke onset, treated with study drug (nerinetide or placebo; randomised 1:1), and selected for reperfusion with thrombolysis, endovascular thrombectomy, or both. The primary endpoint was the number of responders at day 90, which was defined as people with a favourable outcome as per the primary endpoint prespecified in their respective trial. The primary endpoint was analysed by logistic regression, adjusted for age, stroke severity, and trial. FINDINGS: Between March 26, 2015, and Jan 31, 2023, 2487 participants were enrolled in the three trials, of whom 690 met criteria for this pooled analysis (389 participants in the nerinetide group and 301 participants in the placebo group). 364 (53%) of 690 participants were men and 326 (47%) were women. The median age of participants was 76 years (IQR 66-83) and median baseline National Institutes of Health Stroke Scale score was 17 (11-21). 216 (56%) of 389 participants were responders at day 90 in the nerinetide group compared with 144 (48%) of 301 in the placebo group (adjusted odds ratio [aOR] 1·48, 95% CI 1·07-2·06; p=0·017). 62 (16%) of 389 people in the nerinetide group died compared with 55 (18%) of 301 people in the placebo group (aOR 0·81, 95% CI 0·53-1·24; p=0·34). No safety concerns were identified in either group. INTERPRETATION: Nerinetide showed a clinically significant benefit over several outcome measures, including the modified Rankin Scale score, the incidence of stroke worsening, and infarction volumes. Neuroprotection with nerinetide might, therefore, be indicated for patients within 3 h of stroke onset and who are selected for reperfusion. These inclusion criteria should be tested in a future trial. FUNDING: None.
引用
- Tymianski M, Hill MD, Goyal M, et al. Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials. Lancet Neurol. 2025. PMID: 39956129. doi:10.1016/S1474-4422(24)00515-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。